TPST - Tempest Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

TPST is currently covered by 3 analysts with an average price target of $32.13. This is a potential upside of $24.19 (304.66%) from yesterday's end of day stock price of $7.94.

Tempest Therapeutics's activity chart (see below) currently has 2 price targets and 16 ratings on display. The stock rating distribution of TPST is 84.62% BUY and 15.38% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 41.67% with an average time for these price targets to be met of 95.75 days.

Highest price target for TPST is $16, Lowest price target is $9, average price target is $12.5.

Most recent stock forecast was given by JOSEPH PANTGINIS from HC WAINWRIGHT on 10-Apr-2025. First documented stock forecast 06-Jul-2021.

Best performing analysts who are covering TPST - Tempest Therapeutics:

Edward Tenthoff Aydin Huseynov Joseph Pantginis George Farmer

Currently out of the existing stock ratings of TPST, 11 are a BUY (84.62%), 2 are a HOLD (15.38%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$16

$10.05 (168.91%)

1 months 26 days ago
(10-Apr-2025)

0/2 (0%)

$10.14 (173.04%)

Hold

$9

$3.05 (51.26%)

1 months 26 days ago
(10-Apr-2025)

0/2 (0%)

$3.14 (53.58%)

Buy

$104

6 months 23 days ago
(13-Nov-2024)

2/3 (66.67%)

$77.61 (294.09%)

104

Buy

$8

$1.51 (23.27%)

$8

2 years 1 months 9 days ago
(27-Apr-2023)

2/2 (100%)

$5.88 (277.36%)

279

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is TPST (Tempest Therapeutics) average time for price targets to be met?

On average it took 95.75 days on average for the stock forecasts to be realized with a an average price target met ratio 41.67

Which analyst has the current highest performing score on TPST (Tempest Therapeutics) with a proven track record?

EDWARD TENTHOFF

Which analyst has the current lower performing score on TPST (Tempest Therapeutics) with a proven track record?

GEORGE FARMER

Which analyst has the most public recommendations on TPST (Tempest Therapeutics)?

Edward Tenthoff works at PIPER SANDLER and has 5 price targets and 4 ratings on TPST

Which analyst is the currently most bullish on TPST (Tempest Therapeutics)?

Joseph Pantginis with highest potential upside - $10.05

Which analyst is the currently most reserved on TPST (Tempest Therapeutics)?

Edward Tenthoff with lowest potential downside - -$0

Tempest Therapeutics in the News

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular carcinoma (HCC); global investigator support in placeAwarded both Orphan Drug & Fast Track designations for amezalpat based on positive randomized Phase 2 data in first-line HCC Received FDA “Study May Proceed” letter for TPST-1495 in a Phase 2 trial...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?